Correction to “Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2-overexpressing: Preliminary results of a prospective, single-arm, phase II study”

doi:10.1002/ctm2.70775

Clinical and Translational Medicine ›› 2026, Vol. 16 ›› Issue (8) : e70775

PDF (124KB)

Clinical and Translational Medicine ›› 2026, Vol. 16 ›› Issue (8) :e70775 DOI: 10.1002/ctm2.70775

ERRATUM

Author information +

History +

PDF (124KB)

Cite this article

Download citation ▾

null. Correction to “Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2-overexpressing: Preliminary results of a prospective, single-arm, phase II study”. Clinical and Translational Medicine, 2026, 16 (8) : e70775 DOI:10.1002/ctm2.70775

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

Rights & permissions

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.